ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Roflumilast

Also written as “Roflumilast Cream 0.15%”, “Roflumilast Cream 0.3%” and “ARQ-151 cream 0.05%”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Psoriasis · Dermatitis, Atopic · Asthma · Diabetes Mellitus, Type 2, led by 8 companies.

Drug pageRoflumilast: every studyMany companies study it; this page follows only the 61 they lead. All 118 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 30, 201161 company-led studies, 3 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only340 open or runningphase 4since Mar 30, 2011Jun 9, 2003none ahead
Arcutis Biotherapeutics181 open or runningphase 3since Dec 23, 2019Dec 29, 2017Apr 27, 2028phase 3 · NCT07916480
Huadong Medicineits history only31 open or runningphase 3since Sep 30, 2024Sep 30, 2024Jun 30, 2027phase 3 · NCT07683806
FLUIDDA nvits history only20 open or runningphase 4since Nov 21, 2011Nov 21, 2011none ahead
Integrative Skin Science and Researchits history only11 open or runningphase 4since Apr 23, 2026Apr 23, 2026Aug 2027phase 4 · NCT07560618
Padagisits history only10 open or runningphase 3since Feb 28, 2023Feb 28, 2023none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 2since Jan 25, 2016Jan 25, 2016none ahead
Takedaits history only10 open or runningphase 1since Mar 4, 2014Mar 4, 2014none ahead

Also a collaborator on its studies: Tanabe Pharma, Fougera Pharmaceuticals and Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Arcutis Biotherapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Dec 29, 2017.

  1. Nov 30, 2018Phase 2 study in Plaque PsoriasisNCT03764475 · 332 enrolled · United States, Canada
  2. Apr 10, 2019Phase 2 study in Dermatitis, AtopicNCT03916081 · 136 enrolled · United States, Canada
  3. Nov 3, 2019Phase 1 study in Dermatitis, AtopicNCT04156191 · 101 enrolled · United States
  4. Dec 23, 20192 phase 3 studies in Chronic Plaque PsoriasisNCT04211389, NCT04211363
  5. Jan 15, 2020Phase 1 study in Plaque PsoriasisNCT04279119 · 26 enrolled · United States
  6. Feb 25, 2020Phase 3 study in Chronic Plaque PsoriasisNCT04286607 · 337 enrolled · United States, Canada, Dominican Republic
  7. Nov 30, 2020Phase 2 study in PsoriasisNCT04655313 · 20 enrolled · United States, Canada, Dominican Republic
  8. Feb 5, 2021Phase 2 study in PsoriasisNCT04746911 · 10 enrolled · United States, Canada, Dominican Republic
  9. Feb 24, 20212 phase 3 studies in Atopic Dermatitis EczemaNCT04773600, NCT04773587
  10. Mar 16, 2021Phase 3 study in Atopic Dermatitis EczemaNCT04804605 · 1,220 enrolled · United States, Canada
  11. Apr 11, 2021Phase 3 study in Atopic Dermatitis EczemaNCT04845620 · 652 enrolled · United States, Canada
  12. Aug 25, 2021Phase 3 study in Scalp PsoriasisNCT05028582 · 432 enrolled · United States, Canada
  13. May 5, 2025Phase 2 study in Dermatitis, AtopicNCT06998056 · 101 enrolled · United States, Canada, Dominican Republic
  14. Oct 30, 2026Phase 3 study in Dermatitis, AtopicNCT07916480 · 415 planned · United States

Ahead

  1. Apr 27, 2028Primary completion: phase 3 study in Dermatitis, AtopicNCT07916480

TargetBeta

“An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities”NCIt, by rule
“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 5 targets

ProgramCompanyFurthest phaseStudies
ensifentrineruleMerckphase 317

Studies

All 18 Arcutis Biotherapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07916480Dermatitis, Atopic · United States3RecruitingApr 27, 2028415
NCT06998056Dermatitis, Atopic · United States, Canada, Dominican Republic2CompletedDec 4, 2025101
NCT05028582Scalp Psoriasis · United States, Canada3CompletedJun 3, 2022432
NCT04845620Atopic Dermatitis Eczema · United States, Canada3CompletedJun 1, 2023652
NCT04804605Atopic Dermatitis Eczema · United States, Canada3CompletedMay 28, 20241,220
NCT04773600Atopic Dermatitis Eczema · United States, Canada3CompletedSep 29, 2022683
NCT04773587Atopic Dermatitis Eczema · United States, Canada3CompletedAug 30, 2022654
NCT04746911Psoriasis · United States, Canada, Dominican Republic2CompletedMay 11, 202210
NCT04655313Psoriasis · United States, Canada, Dominican Republic2CompletedJan 12, 202220
NCT04286607Chronic Plaque Psoriasis · United States, Canada, Dominican Republic3CompletedJan 22, 2024337
NCT04279119Plaque Psoriasis · United States1CompletedMar 25, 202126
NCT04211389Chronic Plaque Psoriasis · United States, Canada3CompletedNov 23, 2020442
NCT04211363Chronic Plaque Psoriasis · United States, Canada3CompletedNov 16, 2020439
NCT04156191Dermatitis, Atopic · United States1CompletedMay 2, 2023101
NCT03916081Dermatitis, Atopic · United States, Canada2CompletedNov 4, 2019136
NCT03764475Plaque Psoriasis · United States, Canada2CompletedOct 8, 2020332
NCT03638258Plaque Psoriasis · United States, Canada2CompletedMay 29, 2019331
NCT03392168Psoriasis · United States, Canada2CompletedMay 2, 201891

How it is read

Names in the registry

  • “Roflumilast”, 37 entries
  • “Roflumilast Cream 0.15%”, 5 entries
  • “Roflumilast Cream 0.3%”, 3 entries
  • “ARQ-151 cream 0.05%”, 2 entries
  • “Roflumilast Foam 0.3%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.